April 10, 2025 7:30 AM EDT | Source: Psyched Wellness Ltd.
Toronto, Ontario – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9), a life sciences company dedicated to health and wellness products derived from the Amanita Muscaria mushroom, has made significant strides in the development of its new dietary supplement shot.
The company’s US subsidiary, AME Wellness Inc., in collaboration with the brand development firm Zerkalo LLC, has successfully completed an initial pilot run of the 4 oz dietary supplement shot. The purpose of this pilot was to test the product with a select group of consumers and gather feedback regarding taste, effect, and marketing data essential for the product’s future.
CEO of Psyched Wellness, Jeff Stevens, expressed enthusiasm about the pilot run, stating, ‘We are very excited to share this next phase in the development of our new dietary supplement shot. Zerkalo, our partners in brand development have done an excellent job building this product and we look forward to sharing it in full, when the team is ready to launch.’
The company is also preparing to evaluate its website, third-party logistics, and shipping processes to ensure readiness for product fulfillment leading up to the official launch.
About Psyched Wellness Ltd.: Psyched Wellness Ltd. is focused on researching and developing consumer packaged health products derived from the proprietary Amanita Muscaria mushroom extract, AME-1.
Cautionary Statement: This release contains forward-looking information regarding Psyched Wellness’s future plans and activities, which may be subject to various risks and uncertainties.
For more details, please refer to the full press release.
Comments are closed